• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
IMS Company Profiles: Daiichi Sankyo Product Image

IMS Company Profiles: Daiichi Sankyo

  • Published: May 2011
  • Region: World
  • 123 Pages
  • IMS Health

IMS Company Profiles gives a clear picture of the companies’ strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including R&D pipelines, analysts forecasts and events predicted to impact the future. Use IMS Company Profiles to:
- As a first step to any in-depth competitor analysis exercice
- Understand the influence of companies within therapy areas
- Evaluate the future drivers and potential constraints of companies
- Review independent analysts forecasts and commentaries
- Gain a comprehensive picture of a company's strategic direction

Corporate Structure

Strategy statement

Highlights a company’s strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:

- M&A
- Regional strategies
- Therapeutic focus
- R&D strategy
- Licensing activities
- Commentary on future prospects, including brokers’ overviews
- Interview with a key person (where available), including quotes and opinions
- Forecasting table (top 30 companies only), showing events with major potential impact

Financial Review

Company sales performance as well as analyst’s comments and forecasts.

Company Sales Performance:

- Financial review
- Latest results
- Sales by geographical region & leading country
- Sales by country and subsidiary
- Analysis comments

Product Portfolio

Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.

The section shows:

- Summary table of products facing patent expiry.
- Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts’ forecasts/comments.

R&D Pipelines

Comprehensive details of the projects that the company has in its R&D pipeline including:

- Research pipeline summary table.
- Introduction to the R&D activities of the company.
- Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts’ forecasts.
- Quotes from senior personnel gleaned from conferences may also be included in this section when available.

Key figures

- Sales by business segment.
- Sales by geographical region.

Analyst figures

IMS Sales data

- Pharmaceutical sales by geographical region and leading countries.
- Top 5 third level therapeutic classes.
- Leading international products
- Pharmaceutical sales analysis by age

Employee data

Licensing/Co-Marketing Agreements

Displayed in a tabular format to enable you to have “at a glance” review of the licensing activities of the company.

Three sections are available to review licensing activities:

- Marketed products
- R&D pipeline products
- General research collaborations, including combinatorial chemistry, proprietary technologies etc.

Major Events

Summary of the major events that have affected the company. This includes recent and historical events.

Two sections

- Mergers and Acquisitions
- Other major events

Events are organised in chronological order.

Subsidiaries listing

Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS